Therapy of Hypoparathyroidism With PTH(1–84): A Prospective Six Year Investigation of Efficacy and Safety

CONTEXT: Human recombinant (rh)PTH(1–84) was recently approved for the treatment of refractory hypoparathyroidism, based upon a short-term phase 3 clinical trial. Long-term data are needed, because no time limit was placed on the treatment period. OBJECTIVE: We studied the effect of long-term rhPTH(...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Endocrinol Metab
Prif Awduron: Rubin, Mishaela R., Cusano, Natalie E., Fan, Wen-Wei, Delgado, Yasmine, Zhang, Chengchen, Costa, Aline G., Cremers, Serge, Dworakowski, Elzbieta, Bilezikian, John P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Endocrine Society 2016
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4929839/
https://ncbi.nlm.nih.gov/pubmed/27144931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-4135
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg